John C. McKew
Lumos Pharma (United States)(US)
Publications by Year
Research Areas
Growth Hormone and Insulin-like Growth Factors, Lysosomal Storage Disorders Research, Protein Kinase Regulation and GTPase Signaling, Oxidative Organic Chemistry Reactions, Asymmetric Synthesis and Catalysis
Most-Cited Works
- → Phenotypic screens as a renewed approach for drug discovery(2013)421 cited
- → Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial(2017)320 cited
- → Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs(2014)240 cited
- → Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases(2011)151 cited
- → δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders(2012)123 cited
- → Collaborative Development of 2-Hydroxypropyl-β-Cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease(2014)115 cited
- → β-Keto sulfones as inhibitors of 11β-hydroxysteroid dehydrogenase type I and the mechanism of action(2007)112 cited
- → Mutation Update forGNEGene Variants Associated with GNE Myopathy(2014)112 cited
- → Chemical signatures and new drug targets for gametocytocidal drug development(2014)111 cited
- → Indole Cytosolic Phospholipase A2α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic Acid, Efipladib(2008)88 cited